Amendment to Amended and Restated 2010 Equity Compensation Plan by ProPhase Labs, Inc.
ProPhase Labs, Inc. has amended its 2010 Equity Compensation Plan to increase the total number of shares of company stock available for issuance from 1,800,000 to 2,500,000. This amendment was adopted by the company's Compensation Committee, ratified by the Board of Directors, and executed by the Chief Financial Officer and Chief Operating Officer. All other terms of the original plan remain unchanged.
AMENDMENT TO AMENDED AND RESTATED 2010 EQUITY COMPENSATION PLAN
ProPhase Labs, Inc., a Nevada corporation (the “Company”), hereby adopts this Amendment (this “Amendment”) to the Amended and Restated 2010 Equity Compensation Plan (the ‘Plan”).
WITNESSETH
WHEREAS, the Company’s Compensation Committee adopted the Plan and the Board of Directors (the “Board”) ratified the Plan;
WHEREAS, the Plan was submitted to and ratified by the Company’s stockholders at the Company’s Annual Meeting of Stockholders on May 5, 2010;
WHEREAS, the Plan currently provides that the maximum aggregate number of shares of common stock of the Company (“Company Stock”) that may be issued or transferred under the Plan is 1,800,000 shares;
WHEREAS, the Company desires to amend the Plan to increase the number of shares of Company Stock that may be issued under the Plan by 700,000 shares to a total of 2,500,000 shares of Company Stock; and
WHEREAS, pursuant to Section 11 of the Plan, the Company may amend the Plan.
NOW, THEREFORE, the Plan is hereby amended as follows:
1. The first sentence of Section 3 of the Plan is hereby amended in its entirety to read as follows:
“Subject to this Section 3 and Section 7 of the Plan, the total number of Shares which may be issued under the Plan is equal to 1,600,000 plus a maximum of 900,000 Shares available for issuance under the Prior Plan as of the Effective Date.”
2. Except as expressly amended hereby, the Plan shall remain unchanged and in full force and effect.
IN WITNESS WHEREOF, ProPhase Labs, Inc. has caused this Amendment to be duly executed as of the effective date written above.
PROPHASE LABS, INC. | ||
By: | /s/ Robert V. Cuddihy, Jr. | |
Name: | Robert V. Cuddihy, Jr. | |
Title: | Chief Financial Officer and Chief Operating Officer | |
Date: | May 6, 2013 |